Important research results from five studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease (ILD) are being presented at ATS 2022.
Tag: interstitial lung disease
findings come from a study published in the American Journal of Preventive Medicine. Researchers tracked new lung disease among people who smoke and vape.Read More
Pulmonary fibrosis (PF) is a complex interstitial lung disease that afflicts an estimated 100,000 Americans, with 30-40,000 new cases diagnosed each year.Read More
The FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.Read More
Bayer Pharmaceuticals is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias.Read More